Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)

Citation

• Hutson, T. E., Davis, I. D., Machiels, J. P., de Souza, P. L., Hong, B. F., Rottey, S., . . . Figlin, R. (2007). Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology, 25(18_suppl), 5031. doi:10.1200/jco.2007.25.18_suppl.5031

Digital Object Identifier (doi)

• 10.1200/jco.2007.25.18_suppl.5031

Web Of Science Accession Number

Start Page

• 5031

End Page

• 5031

Volume

• 25

Issue

• 18_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2007

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Hutson, T. E., Davis, I. D., Machiels, J. P., de Souza, P. L., Hong, B. F., Rottey, S., . . . Figlin, R. (2007). Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology, 25(18_suppl), 5031. doi:10.1200/jco.2007.25.18_suppl.5031

Digital Object Identifier (doi)

• 10.1200/jco.2007.25.18_suppl.5031

Web Of Science Accession Number

Start Page

• 5031

End Page

• 5031

Volume

• 25

Issue

• 18_suppl

Place Of Publication